Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France

Drug and Alcohol Dependence

Volumn 126, Issue 1-2, 2012, Pages 13-20

  Pauly, V ^a   Pradel, V ^a,b   Pourcel, L ^c   Nordmann, S ^b   Frauger, E ^b   Lapeyre Mestre, M ^c   Micallef, J ^b   Thirion, X ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Analgesics, Opioid; Multi indicator approach; Opiate substitution treatment; Substance related disorders

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; CODEINE; DEXTROPROPOXYPHENE; DIHYDROCODEINE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; OXYCODONE; TRAMADOL;

ARTICLE; COMPARATIVE STUDY; DRUG ABUSE; DRUG DEPENDENCE; DRUG MONITORING; DRUG PROGRAM; DRUG TRAFFIC; FRANCE; HUMAN; INAPPROPRIATE PRESCRIBING; OPIATE SUBSTITUTION TREATMENT; PRIORITY JOURNAL;

ANALGESICS, OPIOID; BENZODIAZEPINES; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; FRANCE; HUMANS; HYPNOTICS AND SEDATIVES; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PHYSICIANS; PRESCRIPTION DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84867890082     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.03.009     Document Type: Article

References (57)

1. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS), 2001. Sécurité d'emploi des médicaments psychotropes: point d'information sur le Rohypnol (flunitrazepam). Available at: (last accessed on 23.12.2011). http://www.afssaps.fr/Infos-de-securite/Communiques-Points-presse/Securite-d-emploi-des-medicaments-psychotropes-point-d-information-sur-le-Rohypnol-flunitrazepam/(language)/fre-FR.
2. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS), 2008. Centre d'Evaluation et d'Information sur la Pharmacodépendance. DRAMES-Décès en relation avec l'Abus de Médicaments Et de Substances - Résultats de l'enquête 2008.
3. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS), 2011. Rivotril® (clonazépam): Modification des conditions de prescription et de délivrance - Point d'information. Available at: (last accessed on 23.12.2011). http://www.afssaps.fr/Infos-de-securite/Points-d-information/Rivotril-R-clonazepam-Modification-des-conditions-de-prescription-et-de-delivrance-Point-d-information/(language)/fre-FR.
4. Barrau K., Thirion X., Micallef J., Chuniaud-Louche C., Bellemin B., San Marco J.L. Comparison of methadone and high dosage beuprnorphine users in French. Addiction 2001, 96:1433-1441.
5. Birnbaum H.G., White A.G., Schiller M., Waldman T., Cleveland J.M., Roland C.L. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011, 12:657-667.
6. Bœuf O., Lapeyre-Mestre M. Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France. Drug Saf. 2007, 30:265-276.
7. Bunn T.L., Yu L., Spiller H., Singleton M. Surveillance of methadone-related poisonings in Kentucky using multiple data sources. Pharmacoepidemiol. Drug Saf. 2010, 19:124-131.
8. Butler S., Budman S., Licari A., Cassidy T., Lioy K., Dickinson J., Brownstein J., Benneyan J.C., Craig Green T., Katz N. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol. Drug Saf. 2008, 17:1142-1154.
9. Cadet-Taïrou A., Gandilhon M., Lahaie E., Chalumeau M., Coquelin A., Toufik A. Drogues et usages de drogues en France. Etat des lieux et tendances récentes 2007-2009 2010, Neuvième rapport national du dispositif TREND, Saint Denis, OFDT.
10. CDCP (Centers for Disease Control and Prevention) Unintentional and undetermined poisoning deaths--11 states, 1990-2001. MMWR 2004, 53:233-238.
11. Cherny N.I., Baselga J., De Conno F., Radbruch L. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Ann. Oncol. 2010, 21:615-618.
12. Cicero T., Dart C., Inciardi J., Woody E., Schnoll S. The development of a comprehensive risk-management program. Pain Med. 2007, 8:157-171.
13. CNAMTS-Caisse Nationale d'Assurance Maladie des Travailleurs Salariés, 2009. Medic'AM 2004-2008: les statistiques de la CNAMTS sur les médicaments remboursés.
14. Dart R. Monitoring risk: post marketing surveillance and signal detection. Drug Alcohol Depend. 2009, 105:S26-S32.
15. DAWN (Drug Abuse Warning Network), 2011. Detailed tables: National Estimates, drug-related emergency department visits for 2004-2009. Non medical use of pharmaceuticals. (last accessed on 03.04.2011). http://dawninfo.samhsa.gov/data/default.asp%3Fmet=All.
16. Dasgupta N., Bailey E., Cicero T., Inciardi J., Parrino M., Rosenblum A., Dart R. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med. 2010, 11:1078-1091.
17. De Conno F., Ripamonti C., Brunelli C. Opioids purchases and expenditure in nine western European countries: 'are we killing off morphine?. Palliative Med. 2005, 19:179-184.
18. Del Giudice P. Cutaneous complications of intravenous drug use. Br. J. Dermatol. 2004, 150:1-10.
19. Escot S., Fahet G. Usages non substitutifs de la buprenorphine haut dosage. Investigation menée en France, en 2002-2003 2004, Observatoire Français des Drogues et Toxicomanies OFDT.
20. Fourrier A., Letenneur L., Dartigues J., Moore N., Bégaud B. Benzodiazepine use in an elderly community-dwelling population: characteristics of users and factors associated with subsequent use. Eur. J. Clin. Pharmacol. 2001, 57:419-425.
21. Frauger E., Pauly V., Thirion X., Natali F., Pradel V., Reggio P., Rouby F., Coudert H., Micallef J. Estimation of clonazepam abuse liability: a new method using a drug reimbursed drug database. Int. Clin. Psychopharmacol. 2009, 24:318-324.
22. Frauger E., Vigneau C., Orléans V., Thirion X., Jolliet P., Micallef J. La consommation de cannabis chez les sujets présentant un abus, une pharmacodépendance ou sous traitement de substitution de la dépendance aux opiacés: données OPPIDUM 2006 et principales tendances depuis 2004 du réseau des Centres d'évaluation. Therapie 2008, 63:119-127. et le Réseau des CEIP.
23. Fredheim O., Skurtveit S., Breivik H., Borchgrevink P. Increasing use of opioids from 2004 to 2007-pharmacoepidemiological data from a complete national prescription database in Norway. Eur. J. Pain 2010, 14:289-294.
24. Gandilhon, M., Cadet-Taïrou, A., Toufik, A., Evrard, I., 2006. Opiacés, stimulants, hallucinogènes et médicaments détournés en 2005 dans des populations fortement consommatrices. Septième rapport national du dispositif TREND, Saint-Denis, OFDT. no. 52: 3. http://www.ofdt.fr/BDD/publications/docs/eftxmgmc.pdf.
25. Gerada C., Ashworth M. ABC of mental health. Addiction and dependence. I. Illicit drugs. BMJ 1997, 315:297-300.
26. Griffiths R.R., Weerts E.M. Benzodiazepine self-administration in humans and laboratory animals-implications for problems of long-term use and abuse. Psychopharmacology 1997, 134:1-37.
27. Hernandez S.H., Nelson L.S. Prescription drug abuse: insight into the epidemic. Clin. Pharmacol. Ther 2010, 88:307-317.
28. International Narcotics Control Board (INCB), 2009. Report 2009. Available at: (last accessed on 04.07). http://www.incb.org/pdf/annual-report/2009/en/AR_09_English.pdf.
29. Johnston L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E. Monitoring the Future National Survey Results on Drug Use, 1975-2004, vol. II: College Students and Adults Ages 19-45 2005, National Institute on Drug Abuse, Bethesda, MD.
30. Lagnaoui R., Depont F., Fourrier A., Abouelfath A., Bégaud B., Verdoux H., Moore N. Patterns and correlates of benzodiazepine use in the French general population. Eur. J. Clin. Pharmacol. 2004, 60:523-529.
31. Llau M.E., Lapeyre-Mestre M., Plas L., Damase-Michel C., Montastruc J.L. Forged medical prescriptions in a community pharmacy network in Midi-Pyrénées area: assessment of a falsification ratio. Eur. J. Clin. Pharmacol. 2002, 57:911-912.
32. Lavie E., Fatséas M., Denis C., Auriacombe M. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence. Drug Alcohol Depend. 2009, 99:338-344.
33. Lois, A., Fingerhut, M., O, Office of Analysis and Epidemiology, 2008. NCHS Health and Stat Increases in Poisoning and Methadone-Related Deaths: United States, 1999-2005. Available at: (last accessed on 03.04). http://www.cdc.gov/nchs/data/hestat/poisoning/poisoning.pdf.
34. Manchikanti L., Fellows B., Ailinani H., Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010, 13:401-435.
35. Martin-Latry K., Bégaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can!. Pharmacoepidemiol. Drug Saf. 2010, 19:256-265.
36. McCabe S.E., Knight J.R., Teter C., Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 2005, 99:96-106.
37. Micallef-Roll J., Lapeyre-Mestre M. Second Meeting of the French CEIP (Centres d'Evaluation et d'Information sur la Pharmacodépendance). Part I. How to evaluate and prevent the abuse and dependence on hypnotic/anxiolytic drugs?. Thérapie 2009, 64:355-364. on behalf of the Association Françaises des Centres d'Evaluation et d'Information sur la Pharmacodépendance.
38. Ministère de la santé, de la jeunesse, des sports et de la vie associative. Arrêté du 1er avril 2008 relatif à la liste de soins ou traitements susceptibles de faire l'objet de mésusage, d'un usage détourné ou abusif, pris en application de l'article L. 162-4-2 du code de la sécurité sociale. Available at: (last accessed on 01.06.2011). http://www.legifrance.gouv.fr/affichTexte.do;jsessionid=D4E6857854925CD0754A976F18F%208030B.tpdjo17v_1%3FcidTexte=JORFTEXT000018598614%26dateTexte=%26oldAction=rechJO%26c%20ategorieLien=id.
39. Modelon H., Frauger E., Laurenceau D., Thirion X., Mallaret M., Micallef J. Abus et dépendances aux produits psychoactifs: étude de consommations à travers l'enquête OPPIDUM 2004 du réseau des CEIP. Thérapie 2007, 62:337-346. et le réseau des CEIP.
40. Mounteney J., Haugland S. Earlier warning: a multi-indicator approach to monitoring trends in the illicit use of medicines. Int. J. Drug Policy 2009, 20:161-169.
41. National Institute on Drug Abuse, 2010. Prescription drugs abuse and addiction. Available at: (last accessed on 04.07). http://www.nida.nih.gov/PDF/RRPrescription.pdf.
42. OFDT (Observatoire Français des Drogues et Toxicomanies), 2010. Drogues et usages de drogues en France état des lieux et tendances récentes 2007-2009; Janvier 2010. Available on: http://www.ofdt.fr/ofdtdev/live/publi/rapports/rap10/epfxacq1.html.
43. OFDT (Observatoire Français des Drogues et Toxicomanies), 2009. Indicateurs locaux/ILIAD. Drogues licites 2009. PROVENCE-ALPES-COTE D'AZUR. Available at: (last accessed on 23.12.2011). http://www.ofdt.fr/BDD_len/iliad/2009_PROVENCE_ALPES_COTE_D_AZUR.xhtml.
44. Pauly V., Frauger E., Pradel V., Rouby F., Berbis J., Natali F., Reggio P., Coudert H., Micallef J., Thirion X. Which indicators can public health authorities use to monitor prescription drug abuse and evaluate the impact of regulatory measures? Controlling high dosage buprenorphine abuse. Drug Alcohol Depend. 2011, 113:29-36.
45. Pauly V., Pradel V., Frauger E., Micallef J., Thirion X. Evolution of reimbursement of opioids since 2004 from the national data of the General Health Insurance System. Therapie 2011, 66:369-372.
46. Pauly V., Frauger E., Pradel V., Nordmann S., Pourcel L., Natali F., Sciortino V., Lapeyre-Mestre M., Micallef J., Thirion X. Monitoring of benzodiazepine diversion using a multi-indicator approach. Int. Clin. Psychopharmacol. 2011, 26:268-277.
47. Pincus H.A., Tanielian T.L., Marcus S.C., Olfson M., Zarin D.A., Thompson J., Magno Zito J. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA 1998, 279:526-531.
48. Pradel V., Thirion X., Ronfle E., Masut A., Micallef J., Bégaud B. Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database. Pharmacoepidemiol. Drug Saf. 2004, 13:473-481.
49. Pradel V., Frauger E., Thirion X., Ronfle E., Lapierre V., Masut V., Coudert C., Blin O., Micallef J. Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiol. Drug Saf. 2009, 18:36-43.
50. Pradel V., Delga C., Rouby F., Micallef J., Lapeyre-Mestre M. Assessment of abuse potential of benzodiazepines from a prescription database using doctor shopping as an indicator. CNS Drugs 2010, 24:611-620.
51. SAMSHA (Substance Abuse and Mental Health Services Administration). 2010. Drug Abuse Warning Network, 2009: Selected Tables of National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Center for Behavioral Health Statistics and Quality, Excel file Nonmedical Use of Pharmaceuticals. Available at: (last accessed on 18.04). https://dawninfo.samhsa.gov/data/default.asp%3Fmet=All.
52. SAMSHA (Substance Abuse and Mental Health Services Administration), 2010b. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. Available at: (last accessed on 04.08). http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9ResultsP.pdf.
53. Schneider M., Bailey E., Cicero T., Dart R., Inciardi J., Parrino M., Munoz A. Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007. Pharmacoepidemiol. Drug Saf. 2009, 18:778-798.
54. Thirion X., Lapierre V., Micallef J., Ronfle E., Masut A., Pradel V., Coudert C., Mabriez J.C., Sanmarco J.L. Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend. 2002, 65:197-204.
55. Thirion X., Micallef J., Barrau K., Djezzar S., SanMarco J.L., Lagier J.L. Observation of psychoactive substance consumption: methods and results of the French OPPIDUM Programme. Eur. Addict. Res. 2001, 7:32-36.
56. WHO Collaborating Center For Drug Statistics Methodology Classification and DDD Assignment, Guidelines for ATC Classification and DDD Assignment 2010, WHO Collaborating Center For Drug Statistics Methodology, Geneva.
57. Zacny J., Bigelow G., Compton P., Foley K., Iguchi M., Sannerud C. College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 2003, 69:215-232.